When considering what names to put on your watch list, look for stocks with an 80 or higher RS Rating. Beam Therapeutics just met that criteria with a new score of 87.
This unique rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the best-performing stocks typically have an 80 or higher RS Rating in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Beam Therapeutics is trading within a buying range after breaking past a 34.09 buy point in a consolidation. Once a stock moves 5% or higher beyond the initial entry, it's considered out of a proper buy zone.
The company posted 0% EPS growth in its most recent report. Sales increased -17%. The company is expected to report its latest numbers on or around Mar. 4.
Beam Therapeutics earns the No. 138 rank among its peers in the Medical-Biomed/Biotech industry group. Halozyme Therapeutics, Catalyst Pharmaceuticals and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
